CA1248873A - Particles and procedures for the determination of antigens and/or antibodies using the particles - Google Patents
Particles and procedures for the determination of antigens and/or antibodies using the particlesInfo
- Publication number
- CA1248873A CA1248873A CA000454853A CA454853A CA1248873A CA 1248873 A CA1248873 A CA 1248873A CA 000454853 A CA000454853 A CA 000454853A CA 454853 A CA454853 A CA 454853A CA 1248873 A CA1248873 A CA 1248873A
- Authority
- CA
- Canada
- Prior art keywords
- particles
- process according
- antibodies
- antigens
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
- Abstract -The invention concerns particles and a procedure for the simultaneous determination of several antigens or antibodies in a liquid using these particles. The mixture of particles contains populations of particles, which differ from each other in the following way:
Each population exhibits a specific combination of the following characteristics: 1) fluorescent substances with differing emission spectra, 2) quantity of these fluorescent substances, 3) particle size. Each particle population is loaded furthermore with a different type of antibody or antigen. Using this mixture of particles, the simultaneous investigation of several types of antigen or antibody can be carried out a time and effort saving manner. The particle mixture is mixed with the liquid containing the antibodies or antigens to be determined. The subsequent reaction steps correspond to the steps of a conventional immuno-fluorescence procedure. Finally, each particle is measured using a measuring device (e.g. flow cytometer) for its fluorescence (emission spectrum and intensity) and size. One the basis of the measured data, a computer identifies the particle and correlates the measured immunofluorescence with a defined specificity.
Each population exhibits a specific combination of the following characteristics: 1) fluorescent substances with differing emission spectra, 2) quantity of these fluorescent substances, 3) particle size. Each particle population is loaded furthermore with a different type of antibody or antigen. Using this mixture of particles, the simultaneous investigation of several types of antigen or antibody can be carried out a time and effort saving manner. The particle mixture is mixed with the liquid containing the antibodies or antigens to be determined. The subsequent reaction steps correspond to the steps of a conventional immuno-fluorescence procedure. Finally, each particle is measured using a measuring device (e.g. flow cytometer) for its fluorescence (emission spectrum and intensity) and size. One the basis of the measured data, a computer identifies the particle and correlates the measured immunofluorescence with a defined specificity.
Description
\
2 --Particles and proc~dures for the determination of antigens and/or antibodies using the particles The invention concerns a particle and a procedure for the determination of antigens and/or antibodies using these particles.
There are various procedures f~r the determination of antigens or antibodies, bas~d on the principles of agglugination, precipitation, complement binding reaction, immunofluorescence, radioimmunoreaction, enzyme immunoreaction etc. All of these procedures have in common, that only one type of antigen or antibody can be determined at a t~me~
However, it is commonly the case that a search is for several types of antigen or antibody, e.g. for the differential diagnosis of infectious or other diseases, in screening tests in healthy subjects, e.g. in serological diagnosis of tumors (multiple tumor antigens), or in allergy tests (several allergens) or in the determination of the immunological status of the organism. Rccording to this state-of-the-art of the techniques, particular~ investigations have to be performed for each type of antigen or antib`ody which is sought. This represents a~multiple investment of time and materiàl. ~ ~
The object underlying the discovery is to reduce~ the expenditure of time and material in the investigation and determination of several types~of antigen or antibody.
: : ~ :: : :
:
- :;
::;, "
.
According to the present invention, the solution of this problem is possible using a mixture of particles characterized by one or more distinguishable labeling substances. Thus the particles in the mixture can be distînguished on the basis of their different labels. Also on the basis of this fact, the fluorimetrically measured immunoreaction between the antigen or antibody with the particle, loaded with antigens or antibodies, and the antibody or antigen in the liquid to be inYestigated, can be categorized into a particular specificity, which represents the combination of labeling signals of the particles.
Accordingly, in the present invention, there is provided a test agent with labelling for analyzing a plurality of different antigens and/or antibodies in a liquid sample, characterized by neutral carrier particles which are labelled individually or in groups with a fluorescent labelling substance and which are loadable with different antibodies or antigens for determining antigens and/or antibodies.
A further aspect of the present invention is a procedure for the determination of antigens or antibodies l~sing particles variously labeled by labeling substances sele~ted from the group of fluorescing substances, colouring agents or pigments and/or their size, characterized in that said particles are loaded with different antigens or antibodiesa that a mixture of such loaded particles is mixed with a liquid containing the antibodies or antigens to be investigated or determined, and that, after a reaction period in which the antibodies or antigens to be determined are bound ~o the antibodies or antigens fixed to the particles, with which the particles are loaded, the antibodies or antigens are identified by subsequent reaction steps and measurements. Using this procedure, it is possible, through the categori~ation of the reacting antigens or antibodies towards the distinguishable particles of the mixture, to determine the antigens or antibodies by the measurement of immunofluorescence and by probing and analysis of the labels.
`~E3 ~2~7~
~ .
- 3a -The invention is described below in more detail U5i ng the following example, whereby reference is made to the accompanyin9 drawings which illustrate embodiments of the invention as follows:
Figure 1 depicts a particle adapted to the determination of bound antibodies according to the present invention; and Figure 2 depicts a particle adapted to the determination of bound antigens according to the presen~ invention.
A serum is to be investigated for antibody types 2 and 16, e.g.
Akl, Ak2, ..., Akj, ..., Akn. Groups (populations of small particles 4, preferably in the form 'I`qi, of spheres with a diameter of approximately 10 ~m and of a suitable carrier material (plastic or poly-saccharide polymer, e.g. agar), are loaded each with a t~pe of antigen, 6 or 12, Agl, Ag2 ~ A~ ,....
Aqn ~ach type of antigen ist bound to a particular type of particle, which were previously labeled in the following way.
The particles ~ are labeled with a combination of substances 8, whose fluorescence spectrum is defined and can be determined fluorimetrically. The labeling can also be carried out in a simple manner, such that the individual particle populations are only labeled with one fluorescing labeling substance with a particular concentration, differing however from particle population to particle population, or with several labeling substan-ces with a particular concentration, differing however `from particle population to particle population. This type of labeling (labeling with distinguishable concent-rations of the same fluorescing substance) can be combined with labeling with labeling using a combination of fluorescing substances with differing emission spectra. The evaluation is then per~ormed on the basis of the spectrum and/or intensity of the emitted fluores-cence. In this way, using one labeling substance, applied in two distinguishable concentrations (0%
and 100% of a particular concentration), 21 = 2 particle populations can be distinguished (particles with the substance and particles without the substance). If during the labeling, the substance is applied in three distinguishable concentrations, e.g. 0%, 50% and 100 of a given concentration, then 31 = 3 particle populations can be distinguished. With n labeling substances with differing emission spectra, each applied in ~ ~istin-guishable concentration, the~ number of labeling possibi-lities amounts to m , e.g. with three labelin~ substances each in ten distinguishable concentrations, 103 1000 different particle populations can be characterized and identified. The labeling of the particles occurs . . _ _ . . . . .. .
': ` ' ' .~5; ' ' ' ` `
. .
3B~
during or after their production. For each type of antigen ~Agj ), a particle population (Pj ) definable fluorescence spectrophotometrically or by its size is applied. The antigen or antibody is chemically or physically bound to the particle. This is done separately for each type of antigen or antibody. There-after, all the particles are mixed in the desired combination. A mixture of particles Pl , P2 ~ ~ Pj ..., Pn ~ loaded with the respective antigens Ayl , Ag2,..., Agj,..., Agn is thus produced.
This mixture of particles is mixed with the liquid (e.g. blood serum), containing the antibodies to be determined. After a reaction time, the the antibodies to be determined, 16 and 2, bind specifically to the corresponding antigens 12 and 6. After a washing step for the particles using a washing fluid for the removal of non-bound substances, the particles are mixed with a solution o fluorescein-labeled antibodies lO, which react species specifically with the antibodies to be determined. These fluorescein-label~d antibodies react with al~l antibodies (every antigen specificity) o the animal species, from which the antibodies to be determined originate. After the reaction time, in which the antibodies lO are bound to the antibodies 16 and 2, the particles are again washed to remove non-bound fluorescein-labeled antibodies. Then, not only the fluorescence of each individual particle-bound antibody 10 (immunofluorescence as a parameter for the immune reaction which has taken place) is measured, but also the fluorescence label which identifies the particle, the size of the particle using a suitable measuring device, are also measured. A flow~cytometer which measures the fluorescence data (and also the size) of each individual particle is suitable for this. The data are processed by ~ computer, whereby ' . , 7;3 the immunofluorescence is appointed to the appropriate particle population. In this way, a profile of the various antigen-antibody reactions Ag 1 Ak1 ,..~Agn Akn is presented.
The procedure described above is equally applicable to the determination of antigens 12 in the liquid to be investigated. In this case, after the first reaction and washing step, a mixture of antibodies 16 towards all the antigens to be investigated is added. These antibodies originate preferably from another animal species than antibodies 14. After renewed reaction and washing step, the fluorescein-labeled antibodies 10, which react species specifically with the antibodies 16, are added. The measurement follows as in the investigations for antibodies.
The procedure can also be carried out in the following way, which deviates from the flow-cytometry:
The particle mixture is fixed to a slide, e.g. to the base of a microtitre plate. The serum to be investi-gated is then applied to this slide (particle mosaic).
After a reaction time, the antibodies present in the serum bind to the corresponding antigens on the particles.
The non-bound substances are removed by subsequent washing.
In a second step, a fluorescence-labeled globulin antibody 10 is applied, which is speclfic for the animal species from which the antibodies to be investi-gated 2 or 16 originate. In this second reaction, the fluorescence-labeled globulin antibody~ 10 binds to the antibodies (globulins) 2 and 16, which were bound to the particles 4 ln the first reaction step.
The non-bound material is removed in a further washing step. ~ ~
,~
~' , The preparation is the(h investigated photometrically using a fluorescence photomicroscope, which is fitted out with filters etc, so that it can measure the spectrum and intensity of the fluorescence radiation emitted by~
a single particle. For the investigation, it is expedient to guide the detector of a fluorescence microscope in a predetermined course, e.g. columnwise, over the particle mixture on the slide which is to be investigat~d.
This can also be performed automatically with a suitable appliance, where required.
The data are evaluated using a comFuter. The investigated particle is indentified on the basis of the fluorescence spctrum of the labels containéd in the particle, e.g.
as particle Pj . Thus, the measured fluorescence, which derives from the globulin antibody (immunofluorescence) can be attributed to the immunological reaction Agj Akj . In this way, the emission data of a large number of particles can be gathered one after the other automatically, and evaluated by the computer.
The data of all the particle populations can be assimi-lated and processed according to the statistical distri-bution of the particles. Thus, a profile of the different antigen-antibody reactions Ag 1 Akl , Ag 2 Ak2 ,...,AgnAkn can be presented.
The emission spectrum or the emission spectra of the labels of the particles can be excited by a radiation of a wide spectrum; however, a ~efined line of ~he emission spectrum can also be excited by radiation of a defined wavelength or several defined lines through excitation by several defined wavelngths.
. :
:, ::~
: , , ' ' '
There are various procedures f~r the determination of antigens or antibodies, bas~d on the principles of agglugination, precipitation, complement binding reaction, immunofluorescence, radioimmunoreaction, enzyme immunoreaction etc. All of these procedures have in common, that only one type of antigen or antibody can be determined at a t~me~
However, it is commonly the case that a search is for several types of antigen or antibody, e.g. for the differential diagnosis of infectious or other diseases, in screening tests in healthy subjects, e.g. in serological diagnosis of tumors (multiple tumor antigens), or in allergy tests (several allergens) or in the determination of the immunological status of the organism. Rccording to this state-of-the-art of the techniques, particular~ investigations have to be performed for each type of antigen or antib`ody which is sought. This represents a~multiple investment of time and materiàl. ~ ~
The object underlying the discovery is to reduce~ the expenditure of time and material in the investigation and determination of several types~of antigen or antibody.
: : ~ :: : :
:
- :;
::;, "
.
According to the present invention, the solution of this problem is possible using a mixture of particles characterized by one or more distinguishable labeling substances. Thus the particles in the mixture can be distînguished on the basis of their different labels. Also on the basis of this fact, the fluorimetrically measured immunoreaction between the antigen or antibody with the particle, loaded with antigens or antibodies, and the antibody or antigen in the liquid to be inYestigated, can be categorized into a particular specificity, which represents the combination of labeling signals of the particles.
Accordingly, in the present invention, there is provided a test agent with labelling for analyzing a plurality of different antigens and/or antibodies in a liquid sample, characterized by neutral carrier particles which are labelled individually or in groups with a fluorescent labelling substance and which are loadable with different antibodies or antigens for determining antigens and/or antibodies.
A further aspect of the present invention is a procedure for the determination of antigens or antibodies l~sing particles variously labeled by labeling substances sele~ted from the group of fluorescing substances, colouring agents or pigments and/or their size, characterized in that said particles are loaded with different antigens or antibodiesa that a mixture of such loaded particles is mixed with a liquid containing the antibodies or antigens to be investigated or determined, and that, after a reaction period in which the antibodies or antigens to be determined are bound ~o the antibodies or antigens fixed to the particles, with which the particles are loaded, the antibodies or antigens are identified by subsequent reaction steps and measurements. Using this procedure, it is possible, through the categori~ation of the reacting antigens or antibodies towards the distinguishable particles of the mixture, to determine the antigens or antibodies by the measurement of immunofluorescence and by probing and analysis of the labels.
`~E3 ~2~7~
~ .
- 3a -The invention is described below in more detail U5i ng the following example, whereby reference is made to the accompanyin9 drawings which illustrate embodiments of the invention as follows:
Figure 1 depicts a particle adapted to the determination of bound antibodies according to the present invention; and Figure 2 depicts a particle adapted to the determination of bound antigens according to the presen~ invention.
A serum is to be investigated for antibody types 2 and 16, e.g.
Akl, Ak2, ..., Akj, ..., Akn. Groups (populations of small particles 4, preferably in the form 'I`qi, of spheres with a diameter of approximately 10 ~m and of a suitable carrier material (plastic or poly-saccharide polymer, e.g. agar), are loaded each with a t~pe of antigen, 6 or 12, Agl, Ag2 ~ A~ ,....
Aqn ~ach type of antigen ist bound to a particular type of particle, which were previously labeled in the following way.
The particles ~ are labeled with a combination of substances 8, whose fluorescence spectrum is defined and can be determined fluorimetrically. The labeling can also be carried out in a simple manner, such that the individual particle populations are only labeled with one fluorescing labeling substance with a particular concentration, differing however from particle population to particle population, or with several labeling substan-ces with a particular concentration, differing however `from particle population to particle population. This type of labeling (labeling with distinguishable concent-rations of the same fluorescing substance) can be combined with labeling with labeling using a combination of fluorescing substances with differing emission spectra. The evaluation is then per~ormed on the basis of the spectrum and/or intensity of the emitted fluores-cence. In this way, using one labeling substance, applied in two distinguishable concentrations (0%
and 100% of a particular concentration), 21 = 2 particle populations can be distinguished (particles with the substance and particles without the substance). If during the labeling, the substance is applied in three distinguishable concentrations, e.g. 0%, 50% and 100 of a given concentration, then 31 = 3 particle populations can be distinguished. With n labeling substances with differing emission spectra, each applied in ~ ~istin-guishable concentration, the~ number of labeling possibi-lities amounts to m , e.g. with three labelin~ substances each in ten distinguishable concentrations, 103 1000 different particle populations can be characterized and identified. The labeling of the particles occurs . . _ _ . . . . .. .
': ` ' ' .~5; ' ' ' ` `
. .
3B~
during or after their production. For each type of antigen ~Agj ), a particle population (Pj ) definable fluorescence spectrophotometrically or by its size is applied. The antigen or antibody is chemically or physically bound to the particle. This is done separately for each type of antigen or antibody. There-after, all the particles are mixed in the desired combination. A mixture of particles Pl , P2 ~ ~ Pj ..., Pn ~ loaded with the respective antigens Ayl , Ag2,..., Agj,..., Agn is thus produced.
This mixture of particles is mixed with the liquid (e.g. blood serum), containing the antibodies to be determined. After a reaction time, the the antibodies to be determined, 16 and 2, bind specifically to the corresponding antigens 12 and 6. After a washing step for the particles using a washing fluid for the removal of non-bound substances, the particles are mixed with a solution o fluorescein-labeled antibodies lO, which react species specifically with the antibodies to be determined. These fluorescein-label~d antibodies react with al~l antibodies (every antigen specificity) o the animal species, from which the antibodies to be determined originate. After the reaction time, in which the antibodies lO are bound to the antibodies 16 and 2, the particles are again washed to remove non-bound fluorescein-labeled antibodies. Then, not only the fluorescence of each individual particle-bound antibody 10 (immunofluorescence as a parameter for the immune reaction which has taken place) is measured, but also the fluorescence label which identifies the particle, the size of the particle using a suitable measuring device, are also measured. A flow~cytometer which measures the fluorescence data (and also the size) of each individual particle is suitable for this. The data are processed by ~ computer, whereby ' . , 7;3 the immunofluorescence is appointed to the appropriate particle population. In this way, a profile of the various antigen-antibody reactions Ag 1 Ak1 ,..~Agn Akn is presented.
The procedure described above is equally applicable to the determination of antigens 12 in the liquid to be investigated. In this case, after the first reaction and washing step, a mixture of antibodies 16 towards all the antigens to be investigated is added. These antibodies originate preferably from another animal species than antibodies 14. After renewed reaction and washing step, the fluorescein-labeled antibodies 10, which react species specifically with the antibodies 16, are added. The measurement follows as in the investigations for antibodies.
The procedure can also be carried out in the following way, which deviates from the flow-cytometry:
The particle mixture is fixed to a slide, e.g. to the base of a microtitre plate. The serum to be investi-gated is then applied to this slide (particle mosaic).
After a reaction time, the antibodies present in the serum bind to the corresponding antigens on the particles.
The non-bound substances are removed by subsequent washing.
In a second step, a fluorescence-labeled globulin antibody 10 is applied, which is speclfic for the animal species from which the antibodies to be investi-gated 2 or 16 originate. In this second reaction, the fluorescence-labeled globulin antibody~ 10 binds to the antibodies (globulins) 2 and 16, which were bound to the particles 4 ln the first reaction step.
The non-bound material is removed in a further washing step. ~ ~
,~
~' , The preparation is the(h investigated photometrically using a fluorescence photomicroscope, which is fitted out with filters etc, so that it can measure the spectrum and intensity of the fluorescence radiation emitted by~
a single particle. For the investigation, it is expedient to guide the detector of a fluorescence microscope in a predetermined course, e.g. columnwise, over the particle mixture on the slide which is to be investigat~d.
This can also be performed automatically with a suitable appliance, where required.
The data are evaluated using a comFuter. The investigated particle is indentified on the basis of the fluorescence spctrum of the labels containéd in the particle, e.g.
as particle Pj . Thus, the measured fluorescence, which derives from the globulin antibody (immunofluorescence) can be attributed to the immunological reaction Agj Akj . In this way, the emission data of a large number of particles can be gathered one after the other automatically, and evaluated by the computer.
The data of all the particle populations can be assimi-lated and processed according to the statistical distri-bution of the particles. Thus, a profile of the different antigen-antibody reactions Ag 1 Akl , Ag 2 Ak2 ,...,AgnAkn can be presented.
The emission spectrum or the emission spectra of the labels of the particles can be excited by a radiation of a wide spectrum; however, a ~efined line of ~he emission spectrum can also be excited by radiation of a defined wavelength or several defined lines through excitation by several defined wavelngths.
. :
:, ::~
: , , ' ' '
Claims (47)
PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A test agent with labelling for analyzing a plurality of different antigens and/or antibodies in a liquid sample, characterized by neutral carrier particles which are labelled individually or in groups with a fluorescent labelling substance and which are loadable with antibodies or antigens differing from one another for determining antigens and/or antibodies.
2. A test agent according to claim 1, characterized in that said particles are approximately spherical and of approximately the same size.
3. A test agent according to claim 2, characterized in that said particles are of a size in the range of approximately 1 µm to approximately 100 µm.
4. A test agent according to claim 1, characterized in that said particles are applied in several discrete sizes, whereby they can be instrumentally categorized with great certainty, according to their size, into particle populations which can be distinguished one from another, whereby the size of the particles serves as an additional labelling (distinguishing) characteristic.
5. A test agent according to claim 1, characterized in that said particles consist of a material selected from the group consisting of plastic, rubber, polysaccharide polymer (e.g. agar) or another polymer or glass or that said particles are cells, e.g.
erythrocytes.
erythrocytes.
6. A test agent according to claim 2, characterized in that said particles consist of a material selected from the group consisting of plastic, rubber, polysaccharide polymer (e.g. agar) or another polymer or glass or that said particles are cells, e.g.
erythrocytes.
erythrocytes.
7. A test agent according to claim 3, characterized in that said particles consist of a material selected from the group consisting of plastic, rubber, polysaccharide polymer (e.g. agar) or another polymer or glass or that said particles are cells, e.g.
erythrocytes.
erythrocytes.
8. A test agent according to claim 4, characterized in that said particles consist of a material selected from the group consisting of plastic, rubber, polysaccharide polymer (e.g. agar) or another polymer or glass or that said particles are cells, e.g.
erythrocytes.
erythrocytes.
9. A test agent according to claim 1, 2 or 3, characterized in that said particles are loaded by direct binding of the antigen to the particle or characterized in that the particles are initially loaded with the specific antibody and then the antigen is bound to this antibody by immunological reaction (particle-antibody-antigen).
10. A test agent according to claim 4, 5 or 6, characterized in that said particles are loaded by direct binding of the antigen to the particle or characterized in that the particles are initially loaded with the specific antibody and then the antigen is bound to this antibody by immunological reaction (particle-antibody-antigen).
11. A test agent according to claim 7 or 8, characterized in that said particles are loaded by direct binding of the antigen to the particle or characterized in that the particles are initially loaded with the specific antibody and then the antigen is bound to this antibody by immunological reaction (particle-antibody-antigen).
12. A process for the determination of antigens or antibodies using particles variously labelled by labelling substances selected from the group of fluorescing substances, colouring agents or pigments and/or their size, characterized in that said particles are loaded with antigens or antibodies differing from one another, that a mixture of such loaded particles is mixed with a liquid containing the antibodies or antigens to be investigated or determined, and that, after a reaction period in which the antibodies or antigens to be determined are bound to the antibodies or antigens fixed to the particles, with which the particles are loaded, the antibodies or antigens are identified by subsequent reaction steps and measurements.
13. A process according to claim 12, wherein said labelling substances exhibit different but defined emission spectra.
14. A process according to claim 13, wherein said labelling substance is one or more fluorescing substances with predetermined differing concentrations.
15. A process according to claim 14, wherein said labelling substances are positioned on the surface of said particles, embedded within said particles or bound to the molecules of the material of said particles.
16. A process according to claim 15, wherein said particles are approximately spherical and of approximately the same size.
7. A process according to claim 16, wherein the size of said particles is in the range of approximately 1 µm to approximately 100 µm.
18. A process according to claim 17, wherein said particles are applied in several discrete sizes, whereby they can be instrumentally categorized with great certainty, according to their size, into particle populations which can be distinguished one from another, whereby the size of the particle served as an additional labelling (distinguishing) characteristic.
19. A process according to claim 18, wherein said particles consist of a material suitable for loading with antigen or antibody.
20. A process according to claim 19, wherein said material is plastic, rubber, polysaccharide polymer (e.g. agar) or another polymer or glass or wherein said particles are cells, e.g.
erythrocytes.
erythrocytes.
21. A process according to claim 20, wherein the said surfaces of said particles are loaded respectively with different antigens or antibodies.
22. A process according to claim 21, wherein said loading of said particles with said antigen is either carried out by direct binding of the antigen to the particle or such that said particles are initially loaded with the specific antibody and then said antigen is bound to said antibody by immunological reaction (particle-antibody-antigen).
11 3. A process according to claim 19, characterized in that the following procedural steps are carried out for the identification of the bound antibodies:
(a) washing of the particles after completion of the reaction time, for the removal of non-bound substances;
(b) in the case of the investigation of antibodies, addition of a liquid with labelled antibodies, which react species-specifically with the antibodies to be determined or investigated (e.g. anti-human globulin in the investigation of human material);
(c) washing for the removal of non-bound substances; and (d) analysis of the labelling of the individual particles.
(a) washing of the particles after completion of the reaction time, for the removal of non-bound substances;
(b) in the case of the investigation of antibodies, addition of a liquid with labelled antibodies, which react species-specifically with the antibodies to be determined or investigated (e.g. anti-human globulin in the investigation of human material);
(c) washing for the removal of non-bound substances; and (d) analysis of the labelling of the individual particles.
24. A process according to claim 23, wherein fluorescence-labelled antigens are also employed for the determination of antibodies.
25. A process according to claim 19, characterized such that, for the identification of the bound antigens, and before the addition of the liquid with labelled antibodies, a liquid containing a mixture of non-labelled antibodies is added, which reacts specifically with the antigens to be determined, followed by a washing step after the completion of a preset reaction time, and that the labelled antibodies which are used react species specifically with the non-labelled antibodies which are used.
26. A process according to claim 25, wherein fluorescence-labelled antigens are also employed for the determination of antibodies.
27. A process according to claim 24, characterized in that the antibodies or antigens are labelled with fluorescent substances.
12 . A process according to claim 26, characterized in that the antibodies or antigens are labelled with fluorescent substances.
29. A process according to claim 27, characterized in that the fluorescein-labelled antibodies or antigens are added simultaneously with the liquid to be investigated to the particles, or after a certain reaction time following addition of the liquid to be investigated, without prior washing of the particles.
30. A process according to claim 28, characterized in that the fluorescein-labelled antibodies or antigens are added simultaneously with the liquid to be investigated to the particles, or after a certain reaction time following addition of the liquid to be investigated, without prior washing of the particles.
31. A process according to claim 29, characterized in that the washing of the particles after the reaction time with the liquid to be investigated and the fluorescein-labelled antibodies is deleted.
32. A process according to claim 30, characterized in that the washing of the particles after the reaction time with the liquid to be investigated and the fluorescein-labelled antibodies is deleted.
33. A process according to claim 31, characterized in that the analysis is carried out using fluorescence photometry or photometry such that the fluorescence data of each particle are determined (identification fluorescence of the particles and fluorescence of the labelled antibodies) and evaluated.
13 ?. A process according to claim 32, characterized in that the analysis is carried out using fluorescence photometry or photometry such that the fluorescence data of each particle are determined (identification fluorescence of the particles and fluorescence of the labelled antibodies) and evaluated.
35. A process according to claim 33, characterized in that the emission spectrum is excited by radiation with a broad spectrum.
36. A process according to claim 33, characterized in that a certain line of the emission spectrum is excited by radiation of a defined wavelength, or that several discrete lines are excited by radiation with several defined wavelengths.
37. A process according to claim 34, characterized in that the emission spectrum is excited by radiation with a broad spectrum.
38. A process according to claim 34, characterized in that a certain line of the emission spectrum is excited by radiation of a defined wavelength, or that several discrete lines are excited by radiation with several defined wavelengths.
39. A process according to claim 12, characterized in that, for the identification of the particles, the fluorescence spectrum or spectra are measured and evaluated on the basis of wavelength and/or intensity of the fluorescence radiation of the labelling substance or substances and/or the particle size or that the labels of colouring agents or pigments are evaluated on the basis of the reflected light.
14 ?. A process according to claim 18, characterized in that, for the identification of the particles, the fluorescence spectrum or spectra are measured and evaluated on the basis of wavelength and/or intensity of the fluorescence radiation of the labelling substance or substances and/or the particle size or that the labels of colouring agents or pigments are evaluated on the basis of the reflected light.
41. A process according to claim 33 or 39, characterized in that the evaluation is carried out on the basis of the categorization of the immunological reactions which have taken place in one or several antigen/antibody systems.
42. A process according to claim 34 or 40, characterized in that the evaluation is carried out on the basis of the categorization of the immunological reactions which have taken place in one or several antigen/antibody systems.
43. A process according to claim 31, characterized in that the particles are directed through a thin tube in the form of a dispersion (sol or suspension) following the procedural steps in claim 31 in a concentration which permits individual determination, and are measured (flow-cytometer).
44. A process according to claim 32, characterized in that the particles are directed through a thin tube in the form of a dispersion (sol or suspension) following the procedural steps in claim 32 in a concentration which permits individual determinations, and are measured (flow-cytometer).
45. A process according to claim 12, characterized in that a mixture of the labelled and loaded particles is fixed to a carrier.
6. A process according to claim 45, characterized in that said carrier is of plastic or glass.
47. A process according to claim 13 or 45, characterized in that the liquid is added after fixing of the particles.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3318261 | 1983-05-19 | ||
DEP3318261.2 | 1983-05-19 | ||
DEP3322373.4 | 1983-06-22 | ||
DE3322373A DE3322373C2 (en) | 1983-05-19 | 1983-06-22 | Test means and methods for the detection of antigens and / or antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1248873A true CA1248873A (en) | 1989-01-17 |
Family
ID=25810892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000454853A Expired CA1248873A (en) | 1983-05-19 | 1984-05-22 | Particles and procedures for the determination of antigens and/or antibodies using the particles |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0126450B1 (en) |
JP (1) | JPH0754324B2 (en) |
CA (1) | CA1248873A (en) |
DE (2) | DE3322373C2 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206143A (en) * | 1985-11-01 | 1993-04-27 | Smithkline Beecham Corporation | Method and reagents for performing subset analysis using quantitative differences in fluorescence intensity |
US5981180A (en) * | 1995-10-11 | 1999-11-09 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US6449562B1 (en) | 1996-10-10 | 2002-09-10 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US6524793B1 (en) | 1995-10-11 | 2003-02-25 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US6797524B1 (en) | 1996-04-25 | 2004-09-28 | Bioarray Solutions Ltd. | Light-controlled electrokinetic assembly of particles near surfaces |
US6958245B2 (en) | 1996-04-25 | 2005-10-25 | Bioarray Solutions Ltd. | Array cytometry |
US7041510B2 (en) | 1996-04-25 | 2006-05-09 | Bioarray Solutions Ltd. | System and method for programmable illumination pattern generation |
US7056746B2 (en) | 1996-04-25 | 2006-06-06 | Bioarray Solutions Ltd. | Array cytometry |
US7057704B2 (en) | 2000-09-17 | 2006-06-06 | Bioarray Solutions Ltd. | System and method for programmable illumination pattern generation |
US7144119B2 (en) | 1996-04-25 | 2006-12-05 | Bioarray Solutions Ltd. | System and method for programmable illumination pattern generation |
US7291504B2 (en) | 1996-04-25 | 2007-11-06 | Bioarray Solutions Ltd. | Assay involving detection and identification with encoded particles |
US7335153B2 (en) | 2001-12-28 | 2008-02-26 | Bio Array Solutions Ltd. | Arrays of microparticles and methods of preparation thereof |
US7445844B2 (en) | 1997-10-14 | 2008-11-04 | Luminex Corporation | Precision fluorescently dyed polymeric microparticles and methods of making and using same |
US7507588B2 (en) * | 2005-04-20 | 2009-03-24 | Becton, Dickinson And Company | Multiplex microparticle system |
EP2428798A1 (en) | 2010-09-14 | 2012-03-14 | Becton, Dickinson and Company | Fusion analyte cytometric bead assay, and systems and kits for performing the same |
US8148171B2 (en) | 2001-10-09 | 2012-04-03 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US8486629B2 (en) | 2005-06-01 | 2013-07-16 | Bioarray Solutions, Ltd. | Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation |
US8486720B2 (en) | 2000-06-21 | 2013-07-16 | Bioarray Solutions, Ltd. | Arrays of magnetic particles |
US8563247B2 (en) | 2003-10-29 | 2013-10-22 | Bioarray Solutions, Ltd. | Kits for multiplexed nucleic acid analysis by capture of single-stranded DNA produced from double-stranded target fragments |
US8615367B2 (en) | 2003-09-18 | 2013-12-24 | Bioarray Solutions, Ltd. | Number coding for identification of subtypes of coded types of solid phase carriers |
US8691754B2 (en) | 2003-09-22 | 2014-04-08 | Bioarray Solutions, Ltd. | Microparticles with enhanced covalent binding capacity and their uses |
US8712123B2 (en) | 2002-11-15 | 2014-04-29 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
US8795960B2 (en) | 2003-10-28 | 2014-08-05 | Bioarray Solutions, Ltd. | Optimization of gene expression analysis using immobilized capture probes |
US9377388B2 (en) | 1997-03-14 | 2016-06-28 | Trustees Of Tufts College | Methods for detecting target analytes and enzymatic reactions |
US9436088B2 (en) | 2001-06-21 | 2016-09-06 | Bioarray Solutions, Ltd. | Un-supported polymeric film with embedded microbeads |
US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
US10107804B2 (en) | 2001-03-23 | 2018-10-23 | Trustees Of Tufts College | Methods for detecting target analytes and enzymatic reactions |
US10324011B2 (en) | 2013-03-15 | 2019-06-18 | The Trustees Of Princeton University | Methods and devices for high throughput purification |
US10415081B2 (en) | 2001-10-15 | 2019-09-17 | Bioarray Solutions Ltd. | Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection |
US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
US11142746B2 (en) | 2013-03-15 | 2021-10-12 | University Of Maryland, Baltimore | High efficiency microfluidic purification of stem cells to improve transplants |
US11493428B2 (en) | 2013-03-15 | 2022-11-08 | Gpb Scientific, Inc. | On-chip microfluidic processing of particles |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4616658A (en) * | 1985-02-27 | 1986-10-14 | William Shell | Non-radioactively labeled microspheres and use of same to measure blood flow |
ZA867698B (en) * | 1985-10-11 | 1987-07-29 | Smithkline Beckman Corp | Methods and reagents for performing subset analysis |
CA1279008C (en) * | 1985-10-11 | 1991-01-15 | Smith Kline & French Canada Ltd. | Methods and reagents for performing subset analysis |
JP2588174B2 (en) * | 1986-09-08 | 1997-03-05 | 三菱化学株式会社 | Measuring method of antigen-antibody reaction |
SE458968B (en) * | 1987-06-16 | 1989-05-22 | Wallac Oy | BIOSPECIFIC ANALYTICAL PROCEDURE FOR MULTIPLE ANALYTICS WHICH DO NOT INCLUDE PARTICULAR COATING AND LABELING WITH FLUORESCING LABEL SUBSTANCES |
FR2638848B1 (en) * | 1988-11-04 | 1993-01-22 | Chemunex Sa | METHOD OF DETECTION AND / OR DETERMINATION IN A LIQUID OR SEMI-LIQUID MEDIUM OF AT LEAST ONE ORGANIC, BIOLOGICAL OR MEDICINAL SUBSTANCE, BY AN AGGLUTINATION METHOD |
GB9003593D0 (en) * | 1990-02-16 | 1990-04-11 | Pa Consulting Services | Improvements in or relating to fluorescence assays |
DE4113386C2 (en) * | 1991-04-24 | 2000-12-07 | Hoehn Bernd Robert | Hybrid drive arrangement for motor vehicles |
US5369036A (en) * | 1992-07-02 | 1994-11-29 | Becton, Dickinson And Company | Enhancement of signal in immunoassays using microparticles which contain different detectable substances |
ES2051651B1 (en) * | 1992-12-10 | 1995-01-01 | Univ Salamanca | PROCEDURE FOR THE SIMULTANEOUS QUANTIFICATION, IN A SINGLE MEASUREMENT, OF THE MAIN TYPES OF HUMAN LYMPHOCYTES AND THEIR SUB-POPULATIONS. |
AU7170994A (en) * | 1993-06-08 | 1995-01-03 | Chronomed, Inc. | Two-phase optical assay method and apparatus |
EP1726959A3 (en) * | 1996-04-25 | 2007-07-11 | BioArray Solutions Ltd. | Light-controlled electrokinetic Assembly of particles near surfaces |
FR2768519B1 (en) * | 1997-09-18 | 1999-12-10 | Immunotech Sa | METHOD FOR CALIBRATING A LIGAND - ANTI LIGAND TYPE DOSING SYSTEM |
AU760425B2 (en) * | 1998-08-28 | 2003-05-15 | Febit Ferrarius Biotechnology Gmbh | Method and measuring device for determining a plurality of analytes in a sample |
US6642062B2 (en) * | 1998-09-03 | 2003-11-04 | Trellis Bioinformatics, Inc. | Multihued labels |
US6383740B2 (en) | 1999-07-30 | 2002-05-07 | Bioergonomics, Inc. | Methods for simultaneously detecting both members of a binding pair |
JP2004527735A (en) * | 2001-02-13 | 2004-09-09 | スマートビード テクノロジーズ リミティド | Biochemical methods and devices for detecting protein properties |
GB2387903A (en) * | 2002-04-24 | 2003-10-29 | Smartbead Technologies Ltd | Multiparameter analysis using tagged molecules |
ATE339687T1 (en) * | 2002-05-22 | 2006-10-15 | Sysmex Corp | IMMUNOLOGICAL METHODS, DEVICES AND REAGENTS |
US20060134774A1 (en) * | 2002-11-22 | 2006-06-22 | Marligen Biosciences, Inc. | Detection of protease enzymes |
US7326573B2 (en) | 2003-01-10 | 2008-02-05 | Beckman Coulter, Inc. | Assay procedures and apparatus |
DE10323901A1 (en) * | 2003-05-26 | 2005-01-05 | Institut Virion/Serion Gmbh | Method and test means for the examination and / or detection of biomolecules and / or active substances in liquid samples |
US7848889B2 (en) | 2004-08-02 | 2010-12-07 | Bioarray Solutions, Ltd. | Automated analysis of multiplexed probe-target interaction patterns: pattern matching and allele identification |
DE102004041659A1 (en) * | 2004-08-27 | 2006-03-02 | Institut Virion/Serion Gmbh | Test device for the in vitro diagnosis of multi-analyte tests and their use |
DE102006012885A1 (en) * | 2006-03-18 | 2007-09-20 | Institut Virion/Serion Gmbh | Diagnostic test system for the simultaneous, quantitative detection of HIV1 and HIV2 antibodies and / or HIV antigens in human sample material |
JP2009542691A (en) * | 2006-07-06 | 2009-12-03 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | Polychromatic particles of various sizes for angiography |
DE102010043276A1 (en) * | 2010-11-03 | 2012-05-03 | Siemens Aktiengesellschaft | Magnetic cell detection |
US20140235492A1 (en) | 2011-09-20 | 2014-08-21 | Institut National De La Sante Et De La Recherche Medicate (Inserm) | Methods for preparing single domain antibody microarrays |
EP2791679A1 (en) | 2011-12-15 | 2014-10-22 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and kits for diagnosing latent tuberculosis infection |
WO2013152919A1 (en) | 2012-04-11 | 2013-10-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Detection of platelet-derived shed cd31 |
WO2013174988A1 (en) | 2012-05-24 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects |
EP2813850A1 (en) | 2013-06-10 | 2014-12-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting rheumatoid arthritis treatment response |
EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
WO2017167763A1 (en) | 2016-03-29 | 2017-10-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis of haemorrhagic atherothrombotic plaques |
WO2018007555A1 (en) | 2016-07-07 | 2018-01-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for diagnosing cancer |
WO2018189335A1 (en) | 2017-04-13 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
WO2018202792A1 (en) | 2017-05-04 | 2018-11-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prediction of acute respiratory distress syndrome |
WO2019072888A1 (en) | 2017-10-11 | 2019-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting hepatocellular carcinoma treatment response |
WO2019081454A1 (en) | 2017-10-24 | 2019-05-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating intracranial aneurysm |
WO2019106126A1 (en) | 2017-12-01 | 2019-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mdm2 modulators for the diagnosis and treatment of liposarcoma |
WO2019121872A1 (en) | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of liver cancer |
WO2019234196A1 (en) | 2018-06-06 | 2019-12-12 | Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol | In vitro method for the diagnosis or detection of non-tuberculous mycobacteria |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
EP3823672A1 (en) | 2018-07-19 | 2021-05-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Combination for treating cancer |
WO2020148349A1 (en) | 2019-01-16 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Variants of erythroferrone and their use |
JP2022527972A (en) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | How to predict and prevent cancer in patients with premalignant lesions |
WO2020249769A1 (en) | 2019-06-14 | 2020-12-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating ocular diseases related to mitochondrial dna maintenance |
WO2021074391A1 (en) | 2019-10-17 | 2021-04-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing nasal intestinal type adenocarcinomas |
WO2021099573A1 (en) | 2019-11-21 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing and treating chronic myelomonocytic leukemia (cmml) |
EP4110955A1 (en) | 2020-02-28 | 2023-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, prognosing and managing treatment of breast cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2017765C3 (en) * | 1970-04-14 | 1979-08-16 | Hoechst Ag, 6000 Frankfurt | Daytime luminescent pigments, their use and process for their production |
US3853987A (en) * | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
DE2632478A1 (en) * | 1975-07-23 | 1977-02-24 | Coulter Electronics | METHOD FOR DETERMINING AND SEPARATING ANTIGEN AND ANTIBODY IN BLOOD AND OTHER SAMPLES |
IL55816A (en) * | 1978-10-30 | 1982-04-30 | Ames Yissum Ltd | Method for simultaneous immunoassay of several different antibodies and a kit therefor |
US4342739A (en) * | 1979-01-09 | 1982-08-03 | Fuji Photo Film Co., Ltd. | Novel material for immunological assay of biochemical components and a process for the determination of said components |
DE3013209A1 (en) * | 1979-04-30 | 1980-11-06 | Recognition Equipment Inc | Water soluble fluorescent pigment contg. trimellitic acid resin - die, and polymerisation catalyst, for ink for jet printing |
JPS6058420B2 (en) * | 1980-07-09 | 1985-12-19 | 富士写真フイルム株式会社 | Microcapsule group for immune reaction and discrimination method using the same |
GB2123146B (en) * | 1982-06-28 | 1985-09-25 | Abbott Lab | Dual parameter flow immunoassays |
US4499052A (en) * | 1982-08-30 | 1985-02-12 | Becton, Dickinson And Company | Apparatus for distinguishing multiple subpopulations of cells |
-
1983
- 1983-06-22 DE DE3322373A patent/DE3322373C2/en not_active Expired
-
1984
- 1984-05-18 EP EP84105650A patent/EP0126450B1/en not_active Expired - Lifetime
- 1984-05-18 DE DE8484105650T patent/DE3485912D1/en not_active Expired - Lifetime
- 1984-05-19 JP JP59099727A patent/JPH0754324B2/en not_active Expired - Lifetime
- 1984-05-22 CA CA000454853A patent/CA1248873A/en not_active Expired
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206143A (en) * | 1985-11-01 | 1993-04-27 | Smithkline Beecham Corporation | Method and reagents for performing subset analysis using quantitative differences in fluorescence intensity |
US6939720B2 (en) | 1995-10-11 | 2005-09-06 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US5981180A (en) * | 1995-10-11 | 1999-11-09 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US6524793B1 (en) | 1995-10-11 | 2003-02-25 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US7041510B2 (en) | 1996-04-25 | 2006-05-09 | Bioarray Solutions Ltd. | System and method for programmable illumination pattern generation |
US7144119B2 (en) | 1996-04-25 | 2006-12-05 | Bioarray Solutions Ltd. | System and method for programmable illumination pattern generation |
US6958245B2 (en) | 1996-04-25 | 2005-10-25 | Bioarray Solutions Ltd. | Array cytometry |
US6991941B1 (en) | 1996-04-25 | 2006-01-31 | Bioarray Solutions Ltd. | Light-controlled electrokinetic assembly of particles near surfaces |
US8039271B2 (en) | 1996-04-25 | 2011-10-18 | Bioarray Solutions, Ltd. | Assays employing randomly distributed microbeads with attached biomolecules |
US7056746B2 (en) | 1996-04-25 | 2006-06-06 | Bioarray Solutions Ltd. | Array cytometry |
US8309368B2 (en) | 1996-04-25 | 2012-11-13 | Bioarray Solutions, Ltd. | Method of making a microbead array with attached biomolecules |
US6797524B1 (en) | 1996-04-25 | 2004-09-28 | Bioarray Solutions Ltd. | Light-controlled electrokinetic assembly of particles near surfaces |
US7291504B2 (en) | 1996-04-25 | 2007-11-06 | Bioarray Solutions Ltd. | Assay involving detection and identification with encoded particles |
US9400259B2 (en) | 1996-04-25 | 2016-07-26 | Bioarray Solutions, Ltd. | Method of making a microbead array with attached biomolecules |
US8691594B2 (en) | 1996-04-25 | 2014-04-08 | Bioarray Solutions, Ltd. | Method of making a microbead array with attached biomolecules |
US8071393B2 (en) | 1996-04-25 | 2011-12-06 | Bioarray Solutions, Ltd. | Method of analyzing nucleic acids using an array of encoded beads |
US7615345B2 (en) | 1996-04-25 | 2009-11-10 | Bio Array Solutions Ltd. | Arrays formed of encoded beads having oligonucleotides attached |
US7749774B2 (en) | 1996-04-25 | 2010-07-06 | Michael Seul | Arrays formed of encoded beads having ligands attached |
US6449562B1 (en) | 1996-10-10 | 2002-09-10 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US9377388B2 (en) | 1997-03-14 | 2016-06-28 | Trustees Of Tufts College | Methods for detecting target analytes and enzymatic reactions |
US10241026B2 (en) | 1997-03-14 | 2019-03-26 | Trustees Of Tufts College | Target analyte sensors utilizing microspheres |
US7445844B2 (en) | 1997-10-14 | 2008-11-04 | Luminex Corporation | Precision fluorescently dyed polymeric microparticles and methods of making and using same |
US9709559B2 (en) | 2000-06-21 | 2017-07-18 | Bioarray Solutions, Ltd. | Multianalyte molecular analysis using application-specific random particle arrays |
US8486720B2 (en) | 2000-06-21 | 2013-07-16 | Bioarray Solutions, Ltd. | Arrays of magnetic particles |
US7057704B2 (en) | 2000-09-17 | 2006-06-06 | Bioarray Solutions Ltd. | System and method for programmable illumination pattern generation |
US10107804B2 (en) | 2001-03-23 | 2018-10-23 | Trustees Of Tufts College | Methods for detecting target analytes and enzymatic reactions |
US9436088B2 (en) | 2001-06-21 | 2016-09-06 | Bioarray Solutions, Ltd. | Un-supported polymeric film with embedded microbeads |
US8148171B2 (en) | 2001-10-09 | 2012-04-03 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and methods |
US10415081B2 (en) | 2001-10-15 | 2019-09-17 | Bioarray Solutions Ltd. | Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection |
US9611507B2 (en) | 2001-12-28 | 2017-04-04 | Bioarray Solutions, Ltd. | Arrays of microparticles and methods of preparation thereof |
US7335153B2 (en) | 2001-12-28 | 2008-02-26 | Bio Array Solutions Ltd. | Arrays of microparticles and methods of preparation thereof |
US10138511B2 (en) | 2001-12-28 | 2018-11-27 | Bioarray Solutions Ltd. | Arrays of microparticles and methods of preparation thereof |
US9251583B2 (en) | 2002-11-15 | 2016-02-02 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
US8712123B2 (en) | 2002-11-15 | 2014-04-29 | Bioarray Solutions, Ltd. | Analysis, secure access to, and transmission of array images |
US8615367B2 (en) | 2003-09-18 | 2013-12-24 | Bioarray Solutions, Ltd. | Number coding for identification of subtypes of coded types of solid phase carriers |
US8691754B2 (en) | 2003-09-22 | 2014-04-08 | Bioarray Solutions, Ltd. | Microparticles with enhanced covalent binding capacity and their uses |
US8795960B2 (en) | 2003-10-28 | 2014-08-05 | Bioarray Solutions, Ltd. | Optimization of gene expression analysis using immobilized capture probes |
US9637777B2 (en) | 2003-10-28 | 2017-05-02 | Bioarray Solutions, Ltd. | Optimization of gene expression analysis using immobilized capture probes |
US8563247B2 (en) | 2003-10-29 | 2013-10-22 | Bioarray Solutions, Ltd. | Kits for multiplexed nucleic acid analysis by capture of single-stranded DNA produced from double-stranded target fragments |
US7781227B2 (en) * | 2005-04-20 | 2010-08-24 | Becton, Dickinson And Company | Multiplex microparticle system |
US7507588B2 (en) * | 2005-04-20 | 2009-03-24 | Becton, Dickinson And Company | Multiplex microparticle system |
US8486629B2 (en) | 2005-06-01 | 2013-07-16 | Bioarray Solutions, Ltd. | Creation of functionalized microparticle libraries by oligonucleotide ligation or elongation |
EP2428798A1 (en) | 2010-09-14 | 2012-03-14 | Becton, Dickinson and Company | Fusion analyte cytometric bead assay, and systems and kits for performing the same |
US10324011B2 (en) | 2013-03-15 | 2019-06-18 | The Trustees Of Princeton University | Methods and devices for high throughput purification |
US10852220B2 (en) | 2013-03-15 | 2020-12-01 | The Trustees Of Princeton University | Methods and devices for high throughput purification |
US11142746B2 (en) | 2013-03-15 | 2021-10-12 | University Of Maryland, Baltimore | High efficiency microfluidic purification of stem cells to improve transplants |
US11486802B2 (en) | 2013-03-15 | 2022-11-01 | University Of Maryland, Baltimore | Methods and devices for high throughput purification |
US11493428B2 (en) | 2013-03-15 | 2022-11-08 | Gpb Scientific, Inc. | On-chip microfluidic processing of particles |
US10976232B2 (en) | 2015-08-24 | 2021-04-13 | Gpb Scientific, Inc. | Methods and devices for multi-step cell purification and concentration |
Also Published As
Publication number | Publication date |
---|---|
DE3322373C2 (en) | 1986-12-04 |
DE3322373A1 (en) | 1984-11-22 |
JPS6035265A (en) | 1985-02-23 |
EP0126450B1 (en) | 1992-09-09 |
EP0126450A2 (en) | 1984-11-28 |
DE3485912D1 (en) | 1992-10-15 |
JPH0754324B2 (en) | 1995-06-07 |
EP0126450A3 (en) | 1988-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1248873A (en) | Particles and procedures for the determination of antigens and/or antibodies using the particles | |
US5405784A (en) | Agglutination method for the determination of multiple ligands | |
US5236826A (en) | Immunoassay for the detection or quantitation of an analyte | |
US5567627A (en) | Method and composition for the simultaneous and discrete analysis of multiple analytes | |
AU695012B2 (en) | Immunoassay for determination of cells | |
EP0296398B1 (en) | Immunoassay method for detecting antibodies to antigens | |
JPS59195160A (en) | Fluorescent multi-parameter dispersoid analysis | |
EP1448990B1 (en) | Particle-based ligand assay with extended dynamic range | |
JP2008520968A (en) | Blood type determination system and apparatus | |
EP0248892A1 (en) | Particle-bound binding component immunoassay | |
JP2005510706A5 (en) | ||
JPS63255660A (en) | Cell measuring method | |
RU2379691C1 (en) | Method of multianalytic immune assay with using microparticles | |
US5132206A (en) | Fluorescent pigments for tagging biological molecules | |
AU1938197A (en) | Multi-antigen serological diagnosis | |
WO1989003533A1 (en) | Process for detecting biochemical species and apparatus useful therein | |
US20050221379A1 (en) | No-wash bead assay, kit and procedure | |
EP0241042A2 (en) | A method for cell analysis | |
JP4590109B2 (en) | Products and methods for single-parameter and multi-parameter phenotyping of cells | |
WO1997003347A1 (en) | Light transmittance type analytical system, variable transmittance optical component, and test device | |
JPH03272466A (en) | Multiple immunologocal evaluating analyzing system | |
JPS6281567A (en) | Quantification method using particle agglutination reaction | |
JPS6281566A (en) | Quantification method by measurement of fluorescent intensity of fine particle | |
CA1197186A (en) | Method of enumerating serologically selected cell populations | |
NO842501L (en) | PROCEDURE AND METHOD FOR DETECTING ANTIGENS AND / OR ANTIBODIES. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |